| Filed On | Filing |
|---|---|
| 26 Oct 2026 | FORM 424B3 |
| 23 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Other Events
On October 23, 2026, Medicus Pharma Ltd. (the "Company") received written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained co... |
| 19 Oct 2026 | FORM PRE 14A |
| 16 Oct 2026 | FORM 424B3 |
| 16 Oct 2026 |
8-K: Material Modifications to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Medicus Pharma Ltd. (the "Company") effected a 1-for-50 share consolidation (the "Share Consolidation") of the Company's issued and outstanding common shares, no par value (the "Common Shares") by filing Articles of Amendment (the "Artic... |
| 16 Oct 2026 | SCHEDULE 13G/A |
| 07 Oct 2026 | FORM 424B3 |
| 07 Oct 2026 |
8-K: Other Events
Medicus Pharma Ltd. (the "Company") today announced that it will effect a fifty-to-one consolidation (the "Share Consolidation") of the Company's common shares, no par value (the "Common Shares"), to be effective on October 12, 2026. The... |
| 14 Sep 2026 | FORM 424B3 |
| 14 Sep 2026 | SCHEDULE 13D |
| 14 Sep 2026 |
8-K: Termination of a Material Definitive Agreement
On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between the Company and Yorkville (the "SEPA")... |
| 11 Sep 2026 |
8-K: Unregistered Sales of Equity Securities
NASDAQ Capital Market [Member] | Common shares, no par value [Member] |
| 08 Sep 2026 |
Form 4: Smith Andrew Alasdair, Chief Operating Officer
Received 735,294 shares as a grant or award ($125K) · Granted 125,000 Stock Option (right to buy) |
| 08 Sep 2026 |
Form 4: Mehmud Faisal, Chief Medical Officer
Received 1,470,588 shares as a grant or award ($251K) · Granted 250,000 Stock Option (right to buy) |
| 08 Sep 2026 |
Form 4: Brennan Edward J., Chief Scientific Officer
Received 588,235 shares as a grant or award ($100K) · Granted 100,000 Stock Option (right to buy) |
| 08 Sep 2026 |
Form 4: Bonner Carolyn F., President and CFO
Received 1,470,588 shares as a grant or award ($251K) · Granted 250,000 Stock Option (right to buy) |
| 08 Sep 2026 |
Form 4: Bokhari Raza, Director
Received 2,941,176 shares as a grant or award ($501K) · Granted 500,000 Stock Option (right to buy) |
| 03 Sep 2026 | FORM 424B3 |
| 03 Sep 2026 | 8-K: Entry into a Material Definitive Agreement |
| 13 Aug 2026 | FORM 424B3 |
Loading...
